An Investigation on a Novel Anti-tumor Fusion Peptide of FSH33-53-IIKK.

Abstract

A novel fusion peptide FSH33-53-IIKK was designed and expected to combine the follicle stimulating hormone receptor (FSHR) targeting and tumor toxicity. In vitro and in vivo study showed the anti-tumor activity of FSH33-53-IIKK was enhanced compared to that of IIKK only. FSH33-53-IIKK could inhibit the growth of tumor via apoptosis and autophagy pathways. In summary, combining the tumor marker-target peptide and anti-tumor peptide together may be an efficient way to search for better anti-tumor candidates.

• Authors: Runlin Yang, Ping Liu, Donghui Pan, Pengjun Zhang, Zhicheng Bai, Yuping Xu, Lizhen Wang, Junjie Yan, Yongjun Yan, Xingdang Liu, Min Yang
• Journal: Journal of Cancer (J Cancer) Vol. 7 Issue 8 Pg. 1010-9 ( 2016) ISSN: 1837-9664 [Print] Australia
• PMID: 27313792 (Publication Type: Journal Article)